-
Mashup Score: 42Agnostic drug development revisited - 12 day(s) ago
The advent and rapid implementation of tissue-based or circulating tumor DNA next generation sequencing (NGS) in the clinic has enabled the identification of novel actionable genomic alterations present across tumor types[1]. Moreover, the number of agents approved that target specific actionable alterations has also increased enabling a shift in cancer treatment towards more personalized approaches paving the way for the implementation of precision oncology[2]. To date, a number of agents that target specific actionable alterations have shown superiority over standard-of-care cytotoxic agents and are part of the treatment armamentarium in a variety of cancers[3–6].
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 28Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: A review of ongoing trials - 1 month(s) ago
The 5-year mortality rate for colon cancer (CC) patients is as high as 30–50 % notwithstanding the implementation of screening programs leading to earlier diagnosis, the improvements in surgical techniques and the contribution of adjuvant therapy [1,2].
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer - 1 month(s) ago
Lung cancer is the leading cause of cancer deaths worldwide attributing to 1.8 million deaths [1]. Surgical resection is the standard of care for resectable early-stage non-small cell lung carcinoma (NSCLC) [2]. 25–70 % of patients eventually develop a relapse after complete resection [3]. Neoadjuvant therapy is defined as any therapy delivered prior to definitive surgical therapy intended to increase the cure rate [4]. Neoadjuvant therapy has many benefits in its potential to increase survival.
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 105If it’s a target, it’s a pan-cancer target: Tissue is not the issue - 2 month(s) ago
Historically, cancer has been classified and treated on the basis of its organ of origin (e.g., breast or colon or lung cancer), which is determined by light microscopy. However, light microscopy does not uncover the factors that drive tumor formation and progression. Understanding tumor drivers requires molecular technology, which has fortunately advanced at a remarkable rate over the last two decades. As a result, there are now multiple tissue-agnostic Food and Drug Administration (FDA) approvals for patients with cancer (Fig.
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 18A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments - 2 month(s) ago
The epidermal growth factor receptor (EGFR) is a transmembrane protein that influences the pathogenesis in a subset of non-small cell lung cancers (NSCLC) [1]. Activation of EGFR is achieved by somatic mutations that lead to a ligand-independent activation of EGFR and uncontrolled cell growth [2,3]. Over the past decades, multiple tyrosine kinase inhibitors (TKIs) have been developed to inhibit growth of EGFR-mutated NSCLC. These drugs affect the intrinsic mitochondrial apoptotic pathway and thereby induce cell death [4].
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Combination Therapies in Patients with Favorable Risk Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis - 5 month(s) ago
In recent years, there have been significant advancements in the treatment of metastatic renal cell carcinoma (mRCC) with the introduction of combination therapies involving immunotherapy (IO). Particularly, the combination of nivolumab and ipilimumab has demonstrated noteworthy improvements in overall survival (OS) when compared to sunitinib in patients classified as intermediate- and poor-risk according to the “International mRCC Database Consortium (IMDC).” These findings highlight the promising potential of IO-based combination therapies in the management of mRCC [1].
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Hem/OncsTweet
RT @dr_yakupergun: A great review about the present and future of tumor-agnostic treatments👇 @OncoAlert https://t.co/an8Uw1kYoE https://t.…